The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape of several solid tumor types. However, as patient outcomes are heterogeneous, clinical tools to aid in prognostication are needed. The Lung Immune Prognostic Index (LIPI) correlates with outcomes in patients with non-smal...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyers, Daniel E., Stukalin, Igor, Vallerand, Isabelle A., Lewinson, Ryan T., Suo, Aleksi, Dean, Michelle, North, Scott, Pabani, Aliyah, Cheng, Tina, Heng, Daniel Y.C., Bebb, D. Gwyn, Morris, Don G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896022/
https://www.ncbi.nlm.nih.gov/pubmed/31684111
http://dx.doi.org/10.3390/cancers11111713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896022/
https://www.ncbi.nlm.nih.gov/pubmed/31684111
http://dx.doi.org/10.3390/cancers11111713

Ejemplares similares